SALBUTAMOL 0.5% w/v inhalation solution

देश: ऑस्ट्रेलिया

भाषा: अंग्रेज़ी

स्रोत: Department of Health (Therapeutic Goods Administration)

सक्रिय संघटक:

Salbutamol

थमां उपलब्ध:

Pfizer Australia Pty Ltd

INN (इंटरनेशनल नाम):

Salbutamol

सूचना पत्रक

SALBUTAMOL
INHALATION
SOLUTION
CONSUMER MEDICINE INFORMATION
WHAT IS IN THIS LEAFLET
This leaflet answers some common
questions about Salbutamol
Inhalation Solution. It does not
contain all the available information.
It does not take the place of talking to
your doctor or pharmacist.
All medicines have benefits and
risks. Your doctor has weighed the
risks of you taking Salbutamol
Inhalation Solution against the
benefits this medicine is expected to
have for you.
This medicine is likely to be used
while you are at the clinic or in
hospital. If possible, please read this
leaflet carefully before this medicine
is given to you. In some cases this
leaflet may be given to you after the
medicine has been used.
IF YOU HAVE ANY CONCERNS ABOUT
TAKING THIS MEDICINE, ASK YOUR
DOCTOR OR PHARMACIST.
KEEP THIS LEAFLET.
You may need to read it again.
WHAT SALBUTAMOL
INHALATION SOLUTION IS
USED FOR
Salbutamol Inhalation Solution
belongs to a group of medicines
called beta-2-agonists. These work
rapidly to open up the air passages in
your lungs.
Salbutamol is inhaled into the lungs
for the treatment of asthma. Asthma
is a disease where the lining of the
lungs become inflamed (red and
swollen), making it difficult to
breathe. This may be due to an
allergy to house dust mites, smoke,
air-borne pollution and other
irritants. Salbutamol opens up the air
passages in people suffering from
asthma, bronchitis and other
breathing problems. It may also be
used before exercise to keep your air
passages open if you start to wheeze
or have difficulty breathing each time
you exert yourself.
Salbutamol Inhalation Solution may
be used for the management of other
conditions that are not mentioned
above. Your doctor will be able to
tell you about the specific condition
for which you have been prescribed
Salbutamol Inhalation Solution.
This medicine is available only with
a doctor's prescription.
BEFORE YOU USE
SALBUTAMOL INHALATION
SOLUTION
_WHEN YOU MUST NOT BE GIVEN_
_IT_
DO NOT USE SALBUTAMOL INHALATION
SOLUTION IF YOU HAVE AN ALLERGY TO:
•
sa

उत्पाद विशेषताएं

Version: pfpsalbj10312
Supersedes: pfpsalbu10112
Page 1 of 9
PRODUCT INFORMATION
SALBUTAMOL INHALATION SOLUTION
(SALBUTAMOL SULFATE)
NAME OF THE MEDICINE
Salbutamol
sulfate
is
di[(
_RS_
)-2-(1,1-dimethyl)ethylamino-1-[4-hydroxy-3
-
(hydroxymethyl)phenyl]ethanol] sulfate. It is a white or almost white,
crystalline, odourless
powder with a slightly bitter taste. It is freely soluble in water,
slightly soluble in alcohol and
in
ether,
very
slightly
soluble
in
methylene
chloride.
Salbutamol
sulfate
1.2
mg
is
approximately equivalent to 1 mg of salbutamol.
The structural formula is represented below
.
Molecular Formula:
(C
13
H
21
NO
3
)
2
,H
2
SO
4
Molecular Weight:
576.7
CAS Number:
51022-70-9
DESCRIPTION
Salbutamol Inhalation Solution in bottles is a clear nebuliser
solution containing salbutamol
0.5%w/v (5 mg/mL) as Salbutamol Sulfate and benzalkonium chloride as
preservative and
Water for Injections.
Salbutamol Inhalation Solution Sterinebs is a clear, isotonic,
preservative-free nebuliser
solution for single use. Sterinebs contain either
salbutamol 2.5 mg or 5 mg as Salbutamol
Sulfate and sodium chloride and Water for Injections to 2.5 mL.
Version: pfpsalbj10312
Supersedes: pfpsalbu10112
Page 2 of 9
PHARMACOLOGY
CLASS OF DRUG
Selective beta-2 adrenoceptor agonist.
MODE OF ACTION
Salbutamol is a long acting, relatively selective beta-2-receptor
stimulant. Administration by
inhalation results in direct stimulation of beta-2-receptors in
bronchial smooth muscle and
hence bronchodilation. This is thought to be due to stimulation of
adenyl cyclase by
salbutamol, resulting in increased levels of cyclic AMP within cells.
These are thought to
inhibit the entry of calcium ions into the cells, thus inhibiting
smooth muscle contraction.
High levels of cyclic AMP in mast cells may also inhibit the release
of histamine and slow
reacting substance-A (SRS-A). After administration of salbutamol
stimulation of both beta-1
and beta-2 receptors occurs because beta-2 selectivity is not
absolute. This results in the
beta-1 effect of